The partnership with Stada Arzneimittel is directly related to Nexgel's business expansion and revenue potential. Given the scale of the North American market, this strategic move is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term. The confidence level is not at the maximum because the impact will materialize in 2024, and market conditions can change.